GSK starts Phase 3 melanoma trials

GlaxoSmithKline Plc has announced the start of two Phase 3 studies that will evaluate the effectiveness of a new combination therapy for the treatment of patients with BRAF-positive metastatic cutaneous melanoma. The studies will also look at safety.

Location